The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults in the U.S. The sNDA is based on leveraging ...
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results